Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential

Reuters

06-05

Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential

Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer $(BTC.AU)$. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541459850"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541459850\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541459850?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541459850","market":"nz","top_or_hot":-1,"title":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer <a href=\"https://laohu8.com/S/BTC.AU\">$(BTC.AU)$</a>. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-05 14:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer <a href=\"https://laohu8.com/S/BTC.AU\">$(BTC.AU)$</a>. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL7khrMs:1","article_id":"2541459850","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541459850","pubTimestamp":1749104924,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPX":"Compass Therapeutics, Inc."},"translate_title":"Compass Therapeutics Inc.发布公司演示文稿，强调Tovecimig治疗胆道癌的2期数据和未来市场潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":0.9},"content_text":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    \n\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer $(BTC.AU)$. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}